Oric Pharmaceuticals Inc expected to post a loss of 57  cents a share - Earnings Preview

ORIC Pharmaceuticals

18/03/2022 11:19

* Oric Pharmaceuticals Inc  ORIC.OQ   ORIC.O  is expected
to show
no change in quarterly revenue when it reports  results on March
21. 
    * ​Refinitiv's mean analyst estimate for Oric
Pharmaceuticals Inc
is for a loss of 57 cents per share. For the same quarter last
year, the company reported a loss of 84 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $31​, above​ its last closing price
of $6.63. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.57       -0.58      -0.47     Beat    19.3
 Jun. 30 2021  -0.49       -0.49      -0.57     Missed  -15.8
 Mar. 31 2021  -0.48       -0.48      -0.45     Beat    6.7​
 Dec. 31 2020  -0.69       -0.46      -0.84     Missed  -80.9
 ​​Sep.        -0.39       -0.39      -0.41     Missed  -4
 30 2020                                                
 Jun. 30 2020  -0.41       -0.40      -0.51     Missed  -28.7​
 Mar. 31 2020  -0.26       -0.26      -4.46     Missed  -1,589
                                                        .4
 This summary was machine generated March 18 at 11:19 GMT.  All
figures in US dollars  unless otherwise stated